Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) FCF Margin (2016 - 2026)

Aytu Biopharma has reported FCF Margin over the past 13 years, most recently at 24.12% for Q4 2025.

  • Quarterly FCF Margin rose 625.0% to 24.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.11% through Dec 2025, down 144.0% year-over-year, with the annual reading at 3.26% for FY2025, 63.0% down from the prior year.
  • FCF Margin was 24.12% for Q4 2025 at Aytu Biopharma, up from 4.45% in the prior quarter.
  • Over five years, FCF Margin peaked at 30.47% in Q2 2023 and troughed at 38.15% in Q4 2021.
  • The 5-year median for FCF Margin is 7.65% (2024), against an average of 5.97%.
  • Year-over-year, FCF Margin crashed -5454bps in 2022 and then skyrocketed 5624bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 38.15% in 2021, then skyrocketed by 76bps to 9.33% in 2022, then surged by 92bps to 0.72% in 2023, then surged by 2582bps to 17.87% in 2024, then soared by 35bps to 24.12% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's FCF Margin are 24.12% (Q4 2025), 4.45% (Q3 2025), and 18.41% (Q2 2025).